The combination of ezetimibe and a statin provides greater LDL-C reduction by inhibiting both intestinal cholesterol absorption and endogenous production of cholesterol. The present study was designed to examine the influence of ageing, gender, BMI, levels of LDL-C, and HbA1c on the response to ezetimibe add-on therapy. Methods: Patients who had been taking a statin for ＞3 months at the usual dose and whose LDL-C was ＞120 mg/dL were eligible for this study. Patients were assigned to receive add-on ezetimibe at 10 mg once daily for 12 weeks. 
Introduction
Lipids have an important role in the atherogenic process leading to coronary heart disease (CHD). Therapeutic interventions aimed at altering lipoprotein metabolism, particularly lowering LDL cholesterol (LDL-C), are the cornerstone of both primary and secondary prevention of CHD. Strict management of LDL-C is recommended in patients with type 2 diabetes according to various guidelines [1] [2] [3] . Statins inhibit cholesterol production in the liver and are considered to be first-line lipid-lowering therapy because largescale clinical outcome trials have consistently demonstrated their efficacy for reducing LDL-C and, more importantly, for reducing cardiovascular events; however, statin therapy alone is often insufficient to achieve current recommended LDL-C targets 4) , so other strate-exceeded 120 mg/dL. Patients who had been taking a statin for ＞3 months at a standard dose and had LDL-C ＞120 mg/dL were eligible. The subjects were 135 outpatients (59 men and 76 women with a mean age of 62.7 years; range: 30 to 75 years) who had been diagnosed with type 2 diabetes and had been followed up at monthly intervals for over 1 year. Baseline characteristics of the subjects are shown in Table 1 .
Patients were excluded from this study if their medications had been altered within 3 months before the initiation of statin therapy and if they were new patients participating in the diabetes education program for the first time. Patients who experienced events that could influence lipid levels, such as hospitalization or the development of intercurrent disorders, during the 3-month study period were also excluded. Medications that are known to influence lipid metabolism were neither added nor withdrawn during the study. Institutional ethics committee approval for this study was obtained and it was performed in accordance with the Declaration of Helsinki. This was a multicenter observational study.
Patients were assigned to receive add-on ezetimibe at 10 mg once daily for a treatment period of 12 weeks. Blood samples were withdrawn from an antecubital vein before and at the end of the study. HbA1c was measured by high-performance liquid chromatography and the plasma glucose level was measured by the glucose oxidase method. HbA1c levels were measured by high performance liquid chromatography. The value of HbA1c (%) is estimated as the NGSP equivalent value (%) calculated by the formula HbA1c (%)=HbA1c (JDS)(%)＋0.4%, consistent with the relational expression of HbA1c (JDS) (%) measured by the previous Japanese standard substance and measurement methods and HbA1c (NGSP) 16) . Serum TC, TG, and HDL-C were measured by standard enzymatic methods. LDL-C was measured with a direct LDL-C assay kit (choletest-LDL; Sekisui Medical Co. Tokyo, Japan) at an independent laboratory (SRL Inc. Tokyo, Japan).
The participants were asked to report their intake of different food items. Cholesterol intake was calculated from the cholesterol content of daily nutrient according to the fifth revised and enlarged edition of the Standard Tables of Food Composition in Japan   17) .
Statistical Analysis
Continuous variables are presented as the mean± standard deviation (SD), while categorical variables are tabulated as frequencies and percentages. To identify factors associated with the changes in TC, LDL-C, and TG from baseline to week 12, we performed univariate regression analysis. We then conducted mulgies for the regulation of lipid metabolism are required.
Ezetimibe is a novel lipid-lowering compound that selectively inhibits intestinal cholesterol absorption by binding to Niemann-Pick C1 like 1 (NPC1L1) protein, thus reducing total cholesterol (TC) and triglyceride (TG) levels and also inhibiting the development of atherosclerosis in ApoE knockout mice 5, 6) . Clinically, it has been shown in the United States that administration of ezetimibe reduces fasting levels of TC and LDL-C in patients with primary hypercholesterolemia 7) . There is a growing body of evidence that cholesterol absorption is related to the risk of cardiovascular events, suggesting the importance of controlling cholesterol absorption for the prevention of cardiovascular events 8, 9) ; therefore, ezetimibe may be potentially useful for treating patients with hypercholesterolemia and reducing their risk of CHD.
Interestingly, significant interindividual variation has been observed with respect to intestinal cholesterol absorption and LDL-C reduction both at baseline and after ezetimibe treatment 10) . To explore how natural variations of NPC1L1 may influence the response of LDL-C when ezetimibe is added to ongoing statin therapy, several extensive studies have been performed and have demonstrated that NPC1L1 sequence variation influences the response to ezetimibe treatment 11, 12) . It has been reported that intestinal cholesterol absorption is increased in patients with a history of coronary artery disease 13) , obesity 14) , or type 2 diabetes mellitus 15) ; however, it is not clear whether the LDL-C lowering effect of ezetimibe differs in relation to factors such as age, sex, obesity, and diabetes in Japanese patients. In addition, to the best of our knowledge, there are limited data about the effect of ezetimibe add-on therapy on LDL-C levels in diabetic patients.
Therefore, the present study was undertaken to assess the influence of ezetimibe add-on therapy on TC and LDL-C levels in subgroups of Japanese type 2 diabetic patients stratified by age, sex, BMI, baseline lipids, and HbA1c, and other clinical characteristics.
Subjects and Methods
Patients with type 2 diabetes mellitus combined with hyperlipidemia who were receiving treatment with an HMG-CoA reductase inhibitor at Yokohama City University Medical Center, Sato Clinic, Tokui Medical Clinic, or Motomachi Takatuka Medical Clinic were enrolled in this study.
Patients who were on statin therapy were eligible for this study if their glycated hemoglobin (HbA1c) was between 6.0 and 9.0% at entry and their LDL-C
Influence of Background Factors
Next, we focused on the efficacy of ezetimibe add-on therapy in different patient subgroups stratified according to gender, baseline age (＜65, vs. ≥ 65 years), BMI (＜25 vs. ≥ 25 kg/m 2 ), baseline TC (＜220 vs. ≥ 220 mg/dL), baseline TG (＜150 vs. ≥ 150 mg/ dL), baseline HDL-C (＜40 vs. ≥ 40 mg/dL), baseline LDL-C (＜140 vs. ≥ 140 mg/dL), basal statin therapy (mild vs. strong), and baseline HbA1c (＜6.5% vs. ≥ 6.5%). As shown in Table 2 , adding ezetimibe to basal statin therapy achieved a significantly greater reduction of TC in male patients than female patients (males: TC −18.0%, TG −14.3%, LDL-C −24.0%; females: TC −12.5, TG 0.0, LDL-C −17.4, p＜0.05). Adding ezetimibe to statin therapy resulted in significantly greater reduction of TC and LDL-C levels in patients with a baseline TC level ≥ 220 mg/dL or LDL-C ≥ 140 mg/dL, than in patients whose baseline TC was ＜220 mg/dL (p＜0.05) or baseline LDL-C was ＜140 mg/dL (p＜0.05). Neither age, baseline TG and HDL-C or the type of statin used was associated with the percent change (% change) of TC and LDL-C; however, the % change of TC and LDL-C tended to be greater for patients with a BMI ≥ 25 kg/m 2 than for patients with a BMI ＜25 kg/m 2 . In addition, the % change of TC and LDL-C was greater in patients with an HbA1c ≥ 6.5% than in patients with an tivariate linear regression analysis to identify independent predictors of the decrease in cholesterol and TG levels. P＜0.05 was considered significant. All statistical analyses were performed with SPSS version 17.0 for Windows (IBM Corporation, NY, USA).
Results

Baseline Characteristics
Assessment of the baseline characteristics of the patients showed significant differences in age, basal HDL-C concentration, and HbA1c between the sexes. The male group was younger and had significantly lower HDL-C than the female group. The two sexes also had a slightly significant difference in the type of statin used. (Table 1) The TC level was reduced by 15.0% (from 223.9 ±37.9 mg/dL to 187.1±29.8 mg/dL, p＜0.001) and LDL-C was reduced by 20.5% (from 140.3±37.3 mg/dL to 108.1±34.7 mg/dL, p＜0.001). In contrast, TG and HDL-C levels did not change significantly from baseline (TG from 175.6±117.5 mg/dL to 154.6 ±104.8 mg/dL, p = 0.08; HDL-C from 54.8±15.9 mg/dL to 55.5±16.3 mg/dL, p = 0.19). ＜140 mg/dL, p = 0.002). Table 5 shows the results of univariate and multivariate regression analyses performed to detect independent predictors of TG reduction. Male sex was an independent predictor of TG reduction (14.0% greater than in females, p = 0.040). In addition, baseline TG ≥ 150 mg/dL was an independent predictor of TG reduction (27.7% greater than when baseline TG was ＜150 mg/dL, p＜0.001).
Improvement of the Lipid Profile After Ezetimibe Treatment
Cholesterol Intake
In order to investigate the mechanisms of different effects of ezetimibe between sexes, randomly selected patients were asked to report their daily intake of different food and beverage items. We then calculated the daily intake of cholesterol. Estimated cholesterol intake was slightly higher in males, but not significantly (male (n=22): 283.2±129.2 mg/day; female (n = 23): 249.2±128.7 mg/day, p = 0.384). HbA1c ＜6.5%. Next, we evaluated the effect of ezetimibe on TG levels in relation to different background factors. Adding ezetimibe to statin therapy resulted in significantly greater reduction of TG levels in patients with a baseline TG ≥ 150 mg/dL than in patients whose baseline TG was ＜150 mg/dL (p＜0.05). Table 3 and 4 show the results of univariate and multivariate regression analyses to identify independent predictors of TC and LDL-C reduction by ezetimibe. After adjusting for age, BMI, and HbA1c, male sex was an independent predictor of greater TC reduction (6.3% greater than in females, p = 0.01), but not of LDL-C reduction. Additionally, baseline LDL-C ≥ 140 mg/dL was an independent predictor of TC reduction (9.8% greater than when baseline LDL-C was ＜140 mg/dL, p = 0.002) as well as LDL-C reduction (14.9% greater than when baseline LDL-C was . We also investigated clinical and laboratory factors associated with the cholesterol-lowering effect of ezetimibe and found that male sex and baseline LDL-C ≥ 140 mg/dL were an independent predictor of a stronger cholesterol-lowering effect. We also
Variables Associated with a Stronger Lipid-Lowering Effect of Add-On Ezetimibe
Discussion
Ezetimibe has been reported to be useful as lipidlowering therapy for patients with hypercholesterolemia; however, only a few studies have examined the efficacy of ezetimibe in Japanese patients with type 2 diabetes 18, 19) . In the present study, we examined the influence of ezetimibe treatment on the lipid profile. high fat diet, a combination of statin and ezetimibe is more effective 26) . We also noted that the male subjects were younger than the female subjects, and young people generally have higher cholesterol consumption. Identifying the precise mechanisms involved in the influence of age and gender on cholesterol absorption requires further investigation to examine the relationship between cholesterol intake and the cholesterollowering effect in each gender.
The effect of ezetimibe on LDL-C was not associated with gender and the following reasons can be suggested. The major abnormality of lipoprotein metabolism in diabetes is related to triglyceride-rich lipoproteins, so many steps in the synthesis of chylomicrons and VLDL particles are abnormal, such as enhanced expression of NPC1-L1, increased expression of intestinal MTP, and increased expression of intestinal ACAT 27) . In addition, clearance of triglyceride-rich lipoproteins is reduced in diabetes, possibly due to impaired LPL activity, so that VLDL and IDL are substantially increased but LDL-C is not markedly increased. In male diabetic patients, TG-rich lipoproteins such as chylomicrons, remnants, and VLDL might be heavily synthesized due to excess intake of cholesterol; therefore, ezetimibe inhibited cholesterol absorption and subsequent synthesis of TG-rich lipoproteins, but not LDL-C, in male diabetic patients.
The decrease of TG achieved in this study was 6.6% and the baseline TG concentration influenced the response to treatment, i.e., the extent of TG reducfound that the decrease of TG was significantly greater in patients with baseline TG ≥ 150 mg/dL.
Since cholesterol absorption is enhanced in patients receiving statin therapy 21) , adding ezetimibe to a statin suppresses cholesterol absorption and thus reduces TC and LDL-C levels. Intestinal cholesterol absorption has been reported to be increased in patients with type 2 diabetes mellitus 15) . In overseas studies, the LDL-C-lowering effect did not differ significantly between the entire study population and hypercholesterolemic patients [22] [23] [24] , but was unclear in diabetic patients. Therefore, we examined whether the TC-and LDL-C-lowering effects of ezetimibe add-on therapy differed in relation to age, gender, obesity, baseline lipid levels, and HbA1c in Japanese diabetic patients. The results showed that gender was an independent predictor of TC and TG reduction after adjustment for covariates such as age and BMI. Why the effect of ezetimibe on TC was affected by gender in the present study, but not in overseas studies, is unclear. This different effect of ezetimibe could reflect ethnic differences in cholesterol intake. The average daily cholesterol intake is 330 mg for men and 280 mg for women in Japan 25) . In diabetic patients, cholesterol intake may be further increased. As shown in the results, cholesterol intake tended to be higher in males than in females; therefore, the different cholesterol-lowering efficiency of ezetimibe might be partially explained by differences in the daily cholesterol intake. In practice, among subjects with a relatively ence lipid levels, including insulin resistance, adipocytokines, and inflammatory markers. Furthermore, the number of patients was limited, so investigation of a larger population will be required to identify other factors that influence the response of LDL-C to ezetimibe therapy. Moreover, to confirm the effect of ezetimibe on type 2 diabetes, we should compare its lipid-lowering effect between patients with and without diabetes.
Strict control of LDL-C is recommended for patients with type 2 diabetes by various guidelines [1] [2] [3] . Statins are first-line lipid-lowering therapy for diabetics, but statins alone after fail to achieve currently recommended LDL-C goals 4) ; therefore, other strategies for the regulation of lipid metabolism are required. According to the present results, ezetimibe may be useful for the treatment of patients with diabetes in whom cholesterol absorption is up regulated, such as men with high HbA1c; therefore, the present findings give some insight into a new cholesterol-lowering strategy for diabetic patients using ezetimibe.
In conclusion, adding ezetimibe to basal statin therapy increases the reduction of TC, LDL-C, and TG in patients with Type 2 diabetes. The efficacy of ezetimibe can be predicted according to clinical characteristics, such as gender and the baseline TG level. tion became greater at high TG concentrations. These results are consistent with those of other studies. In patients who could not reach their LDL-C target on statin monotherapy (13% had type 2 diabetes), addition of ezetimibe decreased TG levels by 20% in those with baseline TG ≥ 131 mg/dL, while the decrease was only 7% in patients with baseline TG ＜131 mg/dL 28) . In the SI-SPECT study 29) baseline TG was considerably higher (263 mg/dL) than in the study performed by Ruggenenti et al.
30) (123 mg/dL), and the decrease of TG was 28.7% 29) and 12% 30) , respectively, in these two studies; therefore, the improvement of TG after adding ezetimibe to basal statin therapy may depend on the initial TG level.
Baseline LDL-C ≥ 140 mg/dL was an independent predictor of the reduction of both TC and LDL-C. These results are not compatible with those of previous studies. In patients with primary hypercholesterolaemia, the response to ezetimibe was consistent between levels of baseline LDL-C 7, 22) . It is unclear whether the LDL-lowering effect of ezetimibe might be different for patients with or without diabetes. In addition, Okada et al. reported that ezetimibe reduced the levels of atherogenic lipoproteins to a greater extent in hypercholesterolemic patients with Type 2 diabetes than in those without diabetes 18) ; however, it has also been stated that the LDL-C-lowering effect of ezetimibe is similar for patients with or without diabetes 24, 31) . In this study, HbA1c was an independent predictor of TC reduction, but the mechanism by which the cholesterol-lowering effect of ezetimibe was enhanced in patients with hyperglycemia is not yet clearly understood. Ezetimibe selectively binds NPC1L1 protein and inhibits the first step of intestinal cholesterol absorption. In patients with diabetes mellitus, NPC1L1 mRNA expression is enhanced, especially when blood glucose is high. Since intestinal cholesterol absorption is enhanced by the increased expression of NPC1L1 15) , the inhibitory effect of ezetimibe on cholesterol absorption would be amplified and a difference between males and females or baseline LDL-C would be detected in patients with diabetes.
Several limitations of this study should be considered when interpreting the results. First, we did not investigate whether cholesterol absorption and synthesis were enhanced in our diabetic patients. We would need to measure cholesterol absorption markers, such as sit sterol and campesterol, and a cholesterol synthesis marker such as lathosterol. Second, we only assessed the efficacy of ezetimibe add-on therapy. In order to confirm the present results, we would also need to study the effect of ezetimibe monotherapy. Third, we did not investigate several factors that influ- 
